KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Free Cash Flow (2018 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Free Cash Flow for 8 consecutive years, with $2.2 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 116.12% to $2.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$46.5 million through Dec 2025, up 51.81% year-over-year, with the annual reading at -$46.5 million for FY2025, 51.81% up from the prior year.
  • Free Cash Flow hit $2.2 million in Q4 2025 for Adaptive Biotechnologies, up from -$5.9 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $2.2 million in Q4 2025 to a low of -$67.4 million in Q1 2022.
  • Historically, Free Cash Flow has averaged -$37.5 million across 5 years, with a median of -$34.5 million in 2022.
  • Biggest five-year swings in Free Cash Flow: plummeted 102.15% in 2021 and later skyrocketed 116.12% in 2025.
  • Year by year, Free Cash Flow stood at -$63.1 million in 2021, then skyrocketed by 53.83% to -$29.1 million in 2022, then grew by 3.05% to -$28.2 million in 2023, then surged by 51.34% to -$13.7 million in 2024, then skyrocketed by 116.12% to $2.2 million in 2025.
  • Business Quant data shows Free Cash Flow for ADPT at $2.2 million in Q4 2025, -$5.9 million in Q3 2025, and -$14.1 million in Q2 2025.